Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • Services & Support
  • Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • Myelodysplastic Syndromes (MDS)
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
      • Results of Study on COVID-19 Vaccine Response in Hematopoietic Cell Transplant Patients Published in eClinicalMedicine
    • Browse Research
    • Education Catalog
      • HLA and Search Strategy Resources
      • GVHD Interactive Provider Network Virtual Learning Series
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • Myelodysplastic Syndromes (MDS)
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
  • Myeloproliferative Neoplasms
Research Spotlight
  • Allogeneic CAR T cell therapy may be a safe and feasible treatment for relapsed refractory multiple myeloma patients

    January 2023

  • New clinical practice guidelines for treating multiple myeloma

    May 2019

  • MRD-negative status prognostic for PFS and OS for patients with multiple myeloma

    March 2019

  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • Multiple Myeloma
  • Email
  • Print This Page

Related Resources

  • HCT Guidelines App
  • Subscribe to the Latest Research
  • All Outcomes and Trends Data

Patient Resources

  • Understanding Bone Marrow Transplant Outcomes
  • Transplant and Multiple Myeloma (PDF)
  • Transplant Basics Booklet
  • Transplant Basics Videos

Multiple Myeloma and Other Plasma Cell Disorders  

Multiple Myeloma 

Approximately 34,000 individuals are diagnosed with multiple myeloma (MM) in the United States each year, with a median age at diagnosis of 69 years. [1] 

MM is the most common indication for hematopoietic cell transplantation (HCT) in the United States. Approximately 96% of transplants in patients with MM are autologous transplants. [2] 

Initial treatment for patients with MM is typically a course of induction therapy, followed by autologous HCT in eligible patients. Allogeneic HCT for MM is generally reserved for patients with high-risk disease. Most allogeneic transplants are performed after an autologous HCT with reduced-intensity or non-myeloablative conditioning regimens. [2,3] 

Light Chain Amyloidosis 

Autologous HCT in amyloidosis has shown improved post-transplantation survival, including both early post-transplant mortality and 5-year survival. [4] 

POEMS syndrome (osteosclerotic myeloma)  

Autologous HCT and high-dose chemotherapy are both treatment options for this rare plasma cell dyscrasia, but longer follow-up is needed to better determine overall survival. [5] 

Outcomes  

Data in this section have been prepared by the CIBMTR® (Center for International Blood and Marrow Transplant Research®). The CIBMTR is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin. 

Figure 1. Survival Trends Over Time, MM Autologous HCT  

Figure 1. Survival Trends Over Time, MM Autologous HCT

Download slide  

Figure 2. Survival After Autologous HCT, MM and Other Plasma Cell Disorders 

Figure 2. Survival After Autologous HCT, MM and Other Plasma Cell Disorders

Download slide 

HCT Consultation Timing Guidelines  

The National Marrow Donor Program® (NMDP)/Be The Match® and the American Society for Transplantation and Cellular Therapy (ASTCT) have jointly developed guidelines for transplant consultation and referral timing based on disease characteristics. [6] The National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines®) were consulted when developing these guidelines and are a valuable tool in determining risk stratification. [7] 

Our guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation. [6]  

Transplant Consultation Guidelines: Multiple Myeloma 

  • At diagnosis 
  • At progression and/or relapse 

Download as a slide 

Transplant Consultation Guidelines: Light Chain Amyloidosis 

  • At diagnosis 
  • At progression and/or relapse 

Download as a slide 

Transplant Consultation Guidelines: POEMS Syndrome (Osteosclerotic Myeloma) 

  • At diagnosis 

Download as a slide 

View complete HCT Consultation Timing Guidelines

Clinical Trials Search and Support  

The NMDP/Be The Match offers the Be The Match® Jason Carter Clinical Trials Search and Support (CTSS) program, which can provide clinical trial navigation to your patients. The CTSS Program was created to help people with blood cancers or blood disorders and their families find and join clinical trials. 

For more information, visit Clinical Trials Search and Support.  

References  

  1. SEER Stat Fact Sheets: Myeloma. Accessed 9 March, 2018. Access 
  2. D'Souza A, Fretham C. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2017. Available at: http://www.cibmtr.org
  3. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008; 111(6): 2962-2972. Access 
  4. D’Souza A, Dispenzieri A, Wirk B, et al. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(32):3741-3749. doi:10.1200/JCO.2015.62.4015. Access 
  5. D’Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 2012;120(1):56-62. doi:10.1182/blood-2012-04-423178. Access 
  6. NMDP/Be The Match and ASTCT Recommended Timing for Transplant Consultation. Download (PDF) 
  7. National Comprehensive Cancer Network. Multiple Myeloma. (Version 3.2023). Access 

  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Keep In Touch

  • Contact Us
  • Transplant Enews

Our Websites

  • Be The Match
  • Be The Match Mexico
  • Be The Match BioTherapies
  • CIBMTR
  • Jason Carter Clinical Trials Search
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright